Clinical Trial Update: Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer [Phase 3]

View source ↗

Summary

A Phase III trial evaluated low-dose 13-cisretinoic acid for prevention of second primaries in patients with Stage I–II head and neck cancer; the study status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• 13-cisretinoic acid (13-cisretinoic acid)

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: Stage I-II Head and Neck Cancer | Phase 3 | Status: COMPLETED